Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

摘要: 167 Background: The addition of H to chemotherapy has improved outcomes in HER2-positive early BC. This approach is associated with (w/) an increased risk (<4%) congestive heart failure (CHF). Dose-dense (every 2 weeks) anthracycline-taxane therapy (Rx) improves survival compared the every 3 week schedule and can be combined w/ anti-HER2 Rx no cardiotoxicity up 36 months. Here we report incidence NYHA Class III/IV CHF phase II studies longer follow-up. Methods: We conducted a retrospective review pts HER2 + stage BC treated at MSKCC DFCI on two trials: In trial A - received dd AC (60/600 mg/m2) x 4 → T (175mg/m2) (w/ pegfilgrastim) 1 year. Trial B differed use weekly (80mg/m2) 12 L (1000mg orally daily) Left ventricular ejection fraction (LVEF) was prospectively assessed by multi-gated acquisition scan serially throughout Rx. Results: enrolled 70 95 w...